Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

被引：197
|
作者：
Hantschel, Oliver [1 ]
Rix, Uwe [1 ]
Superti-Furga, Giulio [1 ]
机构：
[1] Austrian Acad Sci, Ctr Mol Med, A-1090 Vienna, Austria
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 04期
关键词：
BCR-ABL; imatinib; drug targets; chemical proteomics;
D O I：
10.1080/10428190801896103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.
引用
收藏
页码：615 / 619
页数：5
相关论文
共 50 条
  • [1] TOXICITY OF BCR-ABL TYROSINE KINASE INHIBITORS: IMATINIB, DASATINIB AND NILOTINIB
    Sanchez Rocio, Pardo
    Arce Maria, Vuelta
    Mari Pau, Monfort Cervera
    Parada Lucia, Sanchez
    Tardon Leticia, Sanchez-Pacheco
    Vicente Teresa, Aguilella
    ATENCION FARMACEUTICA, 2012, 14 (05): : 343 - 354
  • [2] Systematic profiling and novel targets of the Bcr-Abl kinase inhibitors imatinib, nilotinib and dasatinib
    Hantschel, Oliver
    Rix, Uwe
    Buerckstuemmer, Tilmann
    Schmidt, Uwe
    Kneidinger, Michael
    Bennett, Keiryn L.
    Kaupe, Ines
    Ellmeier, Wilfried
    Valent, Peter
    Superti-Furga, Giulio
    BLOOD, 2007, 110 (11) : 207B - 207B
  • [3] The Prothrombotic Profile of BCR-ABL Inhibitors Ponatinib, Nilotinib and Imatinib
    Loren, Cassandra P.
    Rigg, Rachel A.
    Aslan, Joseph E.
    Healy, Laura D.
    Gruber, Andras
    McCarty, Owen J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34
  • [4] THE PROTHROMBOTIC PROFILE OF BCR-ABL INHIBITORS PONATINIB, NILOTINIB, AND IMATINIB
    Loren, C. P.
    Rigg, R. A.
    Aslan, J. E.
    Healy, L. D.
    Gruber, A.
    McCarty, O. J. T.
    THROMBOSIS RESEARCH, 2014, 133 : S25 - S25
  • [5] Bcr-Abl binding modes of dasatinib, imatinib and nilotinib: An NMR study.
    Manley, Paul W.
    Cowan-Jacob, Sandra W.
    Fendrich, Gabriele
    Strauss, Andre
    Vapai, Navratna
    Grzesiek, Stephan
    Jahnke, Wolfgang
    BLOOD, 2006, 108 (11) : 224A - 224A
  • [6] The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib
    Deadman, Benjamin J.
    Hopkin, Mark D.
    Baxendale, Ian R.
    Ley, Steven V.
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2013, 11 (11) : 1766 - 1800
  • [7] Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
    Rix, Uwe
    Hantschel, Oliver
    Duernberger, Gerhard
    Rix, Lily L. Remsing
    Planyavsky, Melanie
    Fernbach, Nora V.
    Kaupe, Ines
    Bennett, Keiryn L.
    Valent, Peter
    Colinge, Jacques
    Kocher, Thomas
    Superti-Furga, Giulio
    BLOOD, 2007, 110 (12) : 4055 - 4063
  • [8] The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
    Salih, Julia
    Hilpert, Julia
    Placke, Theresa
    Gruenebach, Frank
    Steinle, Alexander
    Salih, Helmut Rainer
    Krusch, Matthias
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (09) : 2119 - 2128
  • [9] Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.
    Hiwase, Devendra K.
    Eadie, Laura
    Saunders, Verity
    Hughes, Timothy
    White, Deborah L.
    BLOOD, 2010, 116 (21) : 1626 - 1627
  • [10] Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein
    Kelvyn M. L. Rocha
    Érica C. M. Nascimento
    João B. L. Martins
    Journal of Molecular Modeling, 2021, 27
12345